Evidence map›Paper›PMID 38077334›Full record

ArticleFrontiers in immunology2023

Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis.

Alessia Provera, Naresh Naik Ramavath, Laila Lavanya Gadipudi, Casimiro Luca Gigliotti, Elena Boggio, Cristina Vecchio, Ian Stoppa, Roberta Rolla, Renzo Boldorini, Mario Pirisi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. ICOSL: more than a trigger of ICOS function.Cell communication and signaling : CCS · 2025
    Review
  4. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Alessia Provera *Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Naresh Naik Ramavath *Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Laila Lavanya GadipudiDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Casimiro Luca GigliottiDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Elena BoggioDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Cristina VecchioDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Ian StoppaDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Roberta RollaDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Renzo BoldoriniDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Mario PirisiTranslational Medicine and Interdisciplinary Research Centre for Autoimmune Diseases, Università del Piemonte Orientale, Novara, Italy.
Carlo SmirneTranslational Medicine and Interdisciplinary Research Centre for Autoimmune Diseases, Università del Piemonte Orientale, Novara, Italy.
Emanuele AlbanoDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Umberto DianzaniDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Salvatore SuttiDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Inducible T-cell Co-Stimulator (ICOS) present on T-lymphocytes and its ligand ICOSL expressed by myeloid cells play multiple roles in regulating T-cell functions. However, recent evidence indicates that reverse signalling involving ICOSL is also important in directing the differentiation of monocyte-derived cells. In this study, we investigated the involvement of ICOS/ICOSL dyad in modulating macrophage functions during the evolution of metabolic dysfunction-associated steatohepatitis (MASH). Results: In animal models of MASH, ICOS was selectively up-regulated on CD8 Conclusions: These results suggest that CD8

Indexed as

CD8-Positive T-LymphocytesFatty LiverAnimalsHumansInducible T-Cell Co-Stimulator LigandInducible T-Cell Co-Stimulator ProteinInterleukin-2LigandsMiceSignal TransductionICOSLG protein, humanIcosl protein, mouseInducible T-Cell Co-Stimulator LigandInducible T-Cell Co-Stimulator ProteinInterleukin-2Ligandschronic inflammationgalectin-3liver fibrosismacrophagesmetabolic dysfunction-associated steatotic liver diseasenonalcoholic fatty liver diseaseosteopontin

Identifiers

PMID38077334
PMCPMC10702974
OpenAlexW4388940559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.